Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris.[5][6] It is a retinoid;[5][7] specifically, a fourth-generation selective retinoic acid receptor (RAR)-γ agonist.[8]
Clinical data | |
---|---|
Trade names | Aklief |
Other names | CD5789 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a620004 |
License data |
|
Pregnancy category | |
Routes of administration | Topical |
Drug class | Skin and mucous membrane agents |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.278.901 |
Chemical and physical data | |
Formula | C29H33NO4 |
Molar mass | 459.586 g·mol−1 |
3D model (JSmol) |
|
| |
|
Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).[9][10] It was approved for medical use in the United States in October 2019.[6][11][12] In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries.[13]
In the United States, trifarotene is indicated for the topical treatment of acne vulgaris in people nine years of age and older.[5] In both Canada and Australia, it is indicated for the topical treatment of acne vulgaris of the face and/or the trunk in people twelve years of age and older.[1][2][3]
Trifarotene was approved for medical use in the United States in October 2019,[12] in Canada in November 2019,[3] and in Australia in January 2021.[1][2]